Company anticipates substantially completing enrollment this year in ongoing Phase 3 RASolute 302 trial of daraxonrasib in previously treated metastatic pancreatic cancer to enable expected data reado ...

What’s New? The European Union and the United Kingdom remain committed “to keep up the pressure on the Kremlin” by way of imposing further ...

Feeling stuck in an endless job hunt? Here are ways innovative AI tools can streamline every stage of your job search.

On track to report initial data from Phase 1/2 clinical trial of PM359 for p47phox CGD in 2025 -- -- IND-enabling studies ongoing for PM577 for Wilson's Disease; expect to file IND and/or CTA in ...

On track to report initial data from Phase 1/2 clinical trial of PM359 for p47phox CGD in 2025 ---- IND-enabling studies ongoing for PM577 for ...

In today’s interconnected world, where companies increasingly outsource control of their IT needs to trusted partners, ...

Organogenesis ( ORGO -5.54%) Q4 2024 Earnings Call Feb 27, 2025, 5:00 p.m. ET ...

President Trump’s executive orders on diversity, climate, gender and perhaps more to come, could lead to major changes in how ...

EDM Resources Inc. is pleased to announce an update on our recent activities and progress on advancing the Scotia Mine to production. "We are pleased to provide an update to our investors on the ...

Following the successful 2023 exploration season and the initiation of underground rehabilitation and development at Nalunaq, Amaroq completed an ambitious 2024 exploration programme, further ...

The London Company Mid Cap portfolio declined 1.8% during the quarter vs. a 0.6% increase in the Russell Midcap Index.

Company anticipates substantially completing enrollment this year in ongoing Phase 3 RASolute 302 trial of daraxonrasib in ...